Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

ClinicalTrials.gov ID: NCT00653328

Public ClinicalTrials.gov record NCT00653328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Atrasentan (ABT-627) Plus DOXIL in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Serous Papillary Adenocarcinoma Following Platinum + Taxane Therapy

Study identification

NCT ID
NCT00653328
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Enrollment
15 participants

Conditions and interventions

Interventions

  • atrasentan hydrochloride Drug
  • doxil Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2003
Primary completion
Feb 28, 2009
Completion
Feb 28, 2009
Last update posted
May 22, 2012

2003 – 2009

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
5
Facility City State ZIP Site status
Central Georgia Hematology Oncology Associates, P.C. Macon Georgia 31201
Kentuckiana Cancer Institute Louisville Kentucky 40202
The Jones Clinic Germantown Tennessee 38138
Jackson-Madison County Hospital Jackson Tennessee 383013956
St. Thomas Health Services Nashville Tennessee 37205
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00653328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 22, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00653328 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →